首頁 > 市場調查報告書 > 醫療設備

心血管設備

市場調查報告書

商品編碼

1493659

分叉病變市場 - 全球產業規模、佔有率、趨勢、機會和預測，按應用（週邊、冠狀動脈）、地區、競爭細分，2019-2029F

Bifurcation Lesions Market - Global Industry Size, Share, Trends, Opportunity, & Forecast, Segmented By Application (Peripheral, Coronary), By Region, Competition, 2019-2029F

出版日期: 2024年05月15日 | 出版商:

TechSci Research | 英文 184 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2023 年全球分叉病變市場估值為22.2 億美元，預計在預測期內將強勁成長，到2029 年複合年成長率為5.89%。和治療治療分叉病變，當主動脈分成兩個較小的分支時會發生分叉病變。

市場概況
預測期	2025-2029
2023 年市場規模	22.2億美元
2029 年市場規模	31.4億美元
2024-2029 年複合年成長率	5.89%
成長最快的細分市場	冠狀動脈
最大的市場	北美洲

全球分叉病變市場涉及醫療設備、手術和療法，旨在解決血管（特別是冠狀動脈）分叉病變所帶來的挑戰。這些病變會限制血流，導致心血管併發症。

主要市場促進因素

心血管疾病盛行率增加

醫療科技的進步

越來越多採用微創手術

醫療保健支出和投資不斷增加

主要市場挑戰

分叉病變治療的複雜性

監管和報銷障礙

開發和研究成本高

主要市場趨勢

微創手術及先進設備

個人化和精準醫療

遠距醫療和遠端監控

細分市場洞察

應用洞察

區域洞察

Global Bifurcation Lesions Market was valued at USD 2.22 billion in 2023 and is anticipated to project robust growth in the forecast period with a CAGR of 5.89% through 2029. The Global Bifurcation Lesions Market encompasses a specialized segment of the medical industry focused on the diagnosis and treatment of bifurcation lesions, which occur when a major artery divides into two smaller branches.

Market Overview
Forecast Period	2025-2029
Market Size 2023	USD 2.22 Billion
Market Size 2029	USD 3.14 Billion
CAGR 2024-2029	5.89%
Fastest Growing Segment	Coronary Vascular
Largest Market	North America

The Global Bifurcation Lesions Market deals with medical devices, procedures, and therapies aimed at addressing the challenges posed by bifurcation lesions in blood vessels, particularly in coronary arteries. These lesions can restrict blood flow, leading to cardiovascular complications.

Key Market Drivers

Increasing Cardiovascular Disease Prevalence

The increasing prevalence of cardiovascular diseases (CVDs) serves as a significant market driver propelling the growth of the Global Bifurcation Lesions Market. Cardiovascular diseases, encompassing conditions like coronary artery disease, heart attacks, and angina, are a leading cause of morbidity and mortality globally. The World Health Organization (WHO) reports that CVDs are responsible for over 17 million deaths annually, making them the leading cause of death worldwide. As lifestyles become more sedentary, diets less healthy, and populations age, the burden of CVDs is projected to continue increasing. Bifurcation lesions are a subset of cardiovascular conditions in which plaque buildup or blockages occur at the junctions where major arteries split into smaller branches. Such lesions can lead to severe complications, including heart attacks and reduced blood flow to vital organs. As the prevalence of CVDs increases, so does the incidence of bifurcation lesions, driving the demand for specialized treatments.

Several risk factors contribute to the rising prevalence of CVDs. These include sedentary lifestyles, poor dietary choices, tobacco use, obesity, and the increasing incidence of conditions like diabetes and hypertension. Lifestyle-related factors are often controllable, but their impact on CVDs continues to rise, necessitating interventions like bifurcation lesion treatment. The global population is aging, and elderly individuals are more susceptible to cardiovascular diseases. As a significant portion of the population enters their senior years, the number of CVD cases is expected to increase. Moreover, elderly patients often have complex medical needs, which can lead to a higher occurrence of bifurcation lesions that require specialized treatment. While CVDs are a global concern, there are geographical variations in their prevalence. High-income countries tend to have a higher burden of CVDs due to factors like unhealthy diets and sedentary lifestyles. However, middle-income and low-income countries are also witnessing an uptick in CVD cases as they undergo economic development and urbanization, which often brings changes in lifestyle and dietary habits.

Advancements in Medical Technologies

Advancements in medical technologies play a crucial role as a market driver for the growth of the Global Bifurcation Lesions Market. Continuous advancements in medical technology have led to the development of innovative devices and treatment options for bifurcation lesions. These include state-of-the-art stents, catheters, and imaging technologies that have significantly improved the effectiveness of interventions and patient outcomes.

One of the notable advancements in treating bifurcation lesions is the introduction of drug-eluting stents. These stents are coated with medications that are slowly released into the blood vessel, reducing the risk of restenosis (re-narrowing of the artery) after the procedure. DES technology has greatly improved the long-term success of treating bifurcation lesions. Advanced imaging techniques, such as intravascular ultrasound (IVUS) and optical coherence tomography (OCT), provide highly detailed images of blood vessels during procedures. These imaging technologies allow physicians to precisely assess the lesion and choose the most appropriate treatment strategy, leading to better patient outcomes and minimizing complications.

Stent technology has evolved to include specialized bifurcation stents designed to address the unique challenges posed by bifurcation lesions. These stents are engineered to ensure proper expansion and coverage of the bifurcation point, reducing the risk of complications and restenosis. Advancements in medical technology have facilitated the growth of minimally invasive procedures for treating bifurcation lesions. These techniques involve smaller incisions, reducing patient discomfort and hospitalization time while improving recovery. Minimally invasive approaches are often less risky and are increasingly preferred by patients and healthcare providers.

Growing Adoption of Minimally Invasive Procedures

The growing adoption of minimally invasive procedures is a significant market driver fueling the growth of the Global Bifurcation Lesions Market. Patients increasingly prefer minimally invasive procedures due to their less invasive nature, shorter recovery times, reduced pain, and lower risk of complications. This patient preference, coupled with the desire of physicians to provide less invasive options, drives the adoption of minimally invasive techniques for treating bifurcation lesions. Minimally invasive procedures often allow patients to resume their normal daily activities sooner compared to traditional open surgeries. This aspect is particularly appealing to individuals with bifurcation lesions, as it minimizes disruptions to their work and personal lives.

Minimally invasive procedures generally require shorter hospital stays, contributing to cost savings for healthcare systems. For bifurcation lesion patients, this translates into lower healthcare expenses and less strain on healthcare resources. Minimally invasive procedures involve smaller incisions, reducing the risk of infection and complications that can occur with open surgeries. This lower risk profile makes minimally invasive techniques a safer option, especially for patients with underlying health conditions. The growth of minimally invasive procedures has been facilitated by advanced imaging technologies such as intravascular ultrasound (IVUS) and optical coherence tomography (OCT). These technologies enable precise visualization of the bifurcation lesion and surrounding blood vessels, aiding interventional cardiologists in making accurate decisions during the procedure.

Rising Healthcare Expenditure and Investment

The rising healthcare expenditure and investment play a significant role as market drivers for the growth of the Global Bifurcation Lesions Market. Governments and healthcare organizations worldwide are allocating more resources to improve cardiovascular care, including the management of conditions like bifurcation lesions. The increased funding facilitates the development and adoption of advanced medical devices, therapies, and techniques for the effective treatment of bifurcation lesions. Healthcare companies are investing heavily in research and development to create innovative solutions for bifurcation lesions. These investments support the development of new medical devices, such as drug-eluting stents and specialized bifurcation stents, which are at the forefront of treating bifurcation lesions effectively.

Substantial investments are made in clinical trials and studies focused on bifurcation lesions. These trials aim to test new devices, procedures, and treatment strategies to improve patient outcomes. They also contribute to the development of evidence-based guidelines for the treatment of bifurcation lesions. Investments in healthcare infrastructure, including the establishment of well-equipped catheterization labs and cardiac care centers, are essential for providing advanced treatment options for bifurcation lesions. These infrastructure investments enhance the capacity to diagnose and treat cardiovascular conditions effectively. Rising healthcare expenditure allows patients to access specialized care for bifurcation lesions, including consultations with experienced interventional cardiologists and access to the latest medical technologies. This contributes to better patient outcomes and increased patient satisfaction.

Key Market Challenges

Complexity of Bifurcation Lesion Treatment

Bifurcation lesions pose a unique set of challenges due to the branching of blood vessels. These complexities include variable lesion morphologies, side branch ostial stenosis, and the risk of restenosis at the bifurcation point. Treating these lesions requires specialized techniques, tools, and stents, which can be challenging for healthcare providers. Additionally, the need for expert knowledge and training in bifurcation lesion management can limit the number of physicians who can effectively perform these procedures, potentially slowing down market growth.

Regulatory and Reimbursement Hurdles

Medical devices and procedures in the cardiovascular field, including those used for bifurcation lesion treatment, are subject to stringent regulatory requirements and approvals. Obtaining regulatory clearance or approval can be a time-consuming and costly process. Furthermore, reimbursement policies vary by region, and reimbursement challenges can affect the adoption of newer and more advanced technologies. Limited or delayed reimbursement for these procedures can discourage healthcare providers from offering them, which can hinder market expansion.

High Development and Research Costs

The research and development of specialized devices, stents, and treatment strategies for bifurcation lesions involve significant costs. Companies investing in these innovations face substantial financial commitments for clinical trials, testing, and regulatory compliance. The lengthy timeframes associated with these processes can also delay the introduction of new technologies to the market. High development costs can subsequently lead to higher prices for these medical devices, potentially limiting patient access and market growth.

Key Market Trends

Minimally Invasive Procedures and Advanced Devices

One significant trend in the Global Bifurcation Lesions Market is the increasing adoption of minimally invasive procedures and the development of advanced medical devices. Interventional cardiologists are increasingly using techniques such as angioplasty and stent placement, which involve smaller incisions and reduce the need for open surgeries. These minimally invasive procedures not only offer patients faster recovery times and lower complication rates but also drive the demand for innovative devices. Advanced devices include drug-eluting stents, bifurcation-specific stents, and specialized balloons designed to treat bifurcation lesions more effectively. As these technologies continue to improve, they are expected to gain more traction in the market, providing better outcomes for patients.

Personalized and Precision Medicine

Another significant trend is the move toward personalized and precision medicine in the treatment of bifurcation lesions. Medical advancements, including intravascular imaging techniques such as intravascular ultrasound (IVUS) and optical coherence tomography (OCT), have enabled interventional cardiologists to assess and tailor treatment plans based on a patient's specific anatomy and lesion characteristics. Additionally, 3D printing technology is being used to create patient-specific stents and devices. These trends emphasize the importance of customized treatment strategies, which can lead to better outcomes and reduced complications for patients with bifurcation lesions.

Telemedicine and Remote Monitoring

The COVID-19 pandemic accelerated the adoption of telemedicine and remote monitoring technologies in healthcare, and this trend has also influenced the management of bifurcation lesions. With telemedicine, patients can consult with healthcare providers, including interventional cardiologists, remotely. Remote monitoring tools allow physicians to keep track of patients' progress after procedures without the need for frequent in-person visits. This trend not only improves patient convenience but also enhances post-procedural care. As technology continues to advance in this area, telemedicine and remote monitoring are expected to play an increasingly significant role in the ongoing care and follow-up of patients with bifurcation lesions.

Segmental Insights

Application Insights

Based on the category of Application, the Coronary Vascular segment emerged as the dominant player in the global market for Bifurcation Lesions in 2023. The primary driver behind the dominance of the Coronary Vascular segment is the high prevalence of coronary artery disease (CAD) globally. CAD is a leading cause of death and morbidity, affecting millions of individuals worldwide. Bifurcation lesions are a common occurrence in CAD, as they occur at the branching points of coronary arteries. As CAD continues to be a significant public health concern, the demand for effective treatment options for coronary bifurcation lesions remains substantial.

There has been a growing awareness of the importance of early detection and management of cardiovascular diseases, including CAD. This increased awareness has led to more individuals seeking medical evaluation and diagnosis for heart-related conditions. Consequently, a higher number of coronary bifurcation lesions are being detected and subsequently treated, further bolstering the prominence of the Coronary Vascular segment.

Technological advancements in the field of interventional cardiology have greatly improved the management of coronary bifurcation lesions. These advancements include the development of specialized bifurcation stents, drug-eluting stents, and intravascular imaging technologies that enhance the precision and effectiveness of coronary interventions. These innovations have made it possible to treat complex bifurcation lesions with minimally invasive techniques, attracting both patients and physicians. Ongoing research and clinical trials are primarily focused on coronary bifurcation lesions due to their clinical significance. These studies contribute to the advancement of knowledge and the development of new and improved treatment options for coronary bifurcation lesions. The abundance of research in this area reinforces the prominence of the Coronary Vascular segment. The prevalence of risk factors associated with CAD, such as obesity, unhealthy dietary habits, smoking, and physical inactivity, continues to rise. These factors contribute to an increased risk of CAD and, by extension, coronary bifurcation lesions. The global burden of these risk factors underscores the enduring demand for treatments in the Coronary Vascular segment. These factors are expected to drive the growth of this segment.

Regional Insights

North America emerged as the dominant region in the global Bifurcation Lesions market in 2023, holding the largest market share in terms of value. This can be ascribed to the significant presence of major market leaders, increased disposable income, a growing demand for drug-eluting stents (DES), and favorable reimbursement policies. Europe held the second-largest market share at 28.8% in 2023, primarily owing to the presence of essential industry players and government initiatives aimed at enhancing healthcare accessibility. In April 2023, Terumo Europe N.V., a medical device company, declared the commencement of a clinical study known as Ultimaster Nagomi.

Key Market Players

Boston Scientific Corp.

Abbott Laboratories Inc.

Cardinal Health Inc.

Medtronic Plc

C. R. Bard, Inc (Becton, Dickinson and Company)

Johnson & Johnson Services, Inc.

Spectranetics Corp (Philips Healthcare)

Terumo Medical Corp.

Poseidon Medical Inc

Report Scope:

In this report, the Global Bifurcation Lesions Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Bifurcation Lesions Market, By Application:

Peripheral Coronary

Bifurcation Lesions Market, By Region:

North America

United States

Canada

Mexico

Europe

France

United Kingdom

Italy

Germany

Spain

Asia-Pacific

China

India

Japan

Australia

South Korea

South America

Brazil

Argentina

Colombia

Middle East & Africa

South Africa

Saudi Arabia

UAE

Kuwait

Turkey

Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Bifurcation Lesions Market.

Available Customizations:

Global Bifurcation Lesions market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Bifurcation Lesions Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Application (Peripheral, Coronary)
- 5.2.2. By Region
- 5.2.3. By Company (2023)
5.3. Market Map

6. North America Bifurcation Lesions Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Application
- 6.2.2. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Bifurcation Lesions Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Application
- 6.3.2. Canada Bifurcation Lesions Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Application
- 6.3.3. Mexico Bifurcation Lesions Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Application

7. Europe Bifurcation Lesions Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Application
- 7.2.2. By Country
7.3. Europe: Country Analysis
- 7.3.1. Germany Bifurcation Lesions Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Application
- 7.3.2. United Kingdom Bifurcation Lesions Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Application
- 7.3.3. Italy Bifurcation Lesions Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Application
- 7.3.4. France Bifurcation Lesions Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Application
- 7.3.5. Spain Bifurcation Lesions Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Application

8. Asia-Pacific Bifurcation Lesions Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Application
- 8.2.2. By Country
8.3. Asia-Pacific: Country Analysis
- 8.3.1. China Bifurcation Lesions Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Application
- 8.3.2. India Bifurcation Lesions Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Application
- 8.3.3. Japan Bifurcation Lesions Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Application
- 8.3.4. South Korea Bifurcation Lesions Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Application
- 8.3.5. Australia Bifurcation Lesions Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Application

9. South America Bifurcation Lesions Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Application
- 9.2.2. By Country
9.3. South America: Country Analysis
- 9.3.1. Brazil Bifurcation Lesions Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Application
- 9.3.2. Argentina Bifurcation Lesions Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Application
- 9.3.3. Colombia Bifurcation Lesions Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Application

10. Middle East and Africa Bifurcation Lesions Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Application
- 10.2.2. By Country
10.3. MEA: Country Analysis
- 10.3.1. South Africa Bifurcation Lesions Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Application
- 10.3.2. Saudi Arabia Bifurcation Lesions Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Application
- 10.3.3. UAE Bifurcation Lesions Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Application
- 10.3.4. Kuwait Bifurcation Lesions Market Outlook
  - 10.3.4.1. Market Size & Forecast
    - 10.3.4.1.1. By Value
  - 10.3.4.2. Market Share & Forecast
    - 10.3.4.2.1. By Application
- 10.3.5. Turkey Bifurcation Lesions Market Outlook
  - 10.3.5.1. Market Size & Forecast
    - 10.3.5.1.1. By Value
  - 10.3.5.2. Market Share & Forecast
    - 10.3.5.2.1. By Application
- 10.3.6. Egypt Bifurcation Lesions Market Outlook
  - 10.3.6.1. Market Size & Forecast
    - 10.3.6.1.1. By Value
  - 10.3.6.2. Market Share & Forecast
    - 10.3.6.2.1. By Application

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Recent Developments
12.2. Product Launches
12.3. Mergers & Acquisitions

13. Global Bifurcation Lesions Market: SWOT Analysis

14. Competitive Landscape

14.1. Boston Scientific Corp.
- 14.1.1. Business Overview
- 14.1.2. Product & Service Offerings
- 14.1.3. Recent Developments
- 14.1.4. Key Personnel
- 14.1.5. SWOT Analysis
- 14.1.6. Financials (As Reported)
14.2. Abbott Laboratories Inc.
14.3. Cardinal Health Inc.
14.4. Medtronic Plc
14.5. C. R. Bard, Inc.(Becton, Dickinson and Company)
14.6. Johnson & Johnson Services, Inc.
14.7. Spectranetics Corp (Philips Healthcare)
14.8. Terumo Medical Corp.
14.9. Poseidon Medical Inc.